Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.64 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.64 |
| ▸ | KDR | P35968 | 1/20 | 0.64 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1190518 | 1.00 | EGFR (0.69) | EGFRERBB2EPHA2KDREPHB4 | |
| SCHEMBL1190515 | 1.00 | EGFR (0.69) | EGFRERBB2EPHA2KDREPHB4 | |
| SCHEMBL1190516 | 1.00 | EGFR (0.69) | EGFRERBB2EPHA2KDREPHB4 | |
| SCHEMBL31038407 | 1.00 | EGFR (0.69) | EGFRERBB2EPHA2KDREPHB4 | |
| Hydrochloric Acid SCHEMBL20532687 | 0.99 | EGFR (0.69) | EGFRERBB2EPHA2KDREPHB4 | |
| Hydrochloric Acid SCHEMBL20532688 | 0.99 | EGFR (0.69) | EGFRERBB2EPHA2KDREPHB4 | |
| SCHEMBL1191094 | 0.95 | EGFR (0.68) | EGFRERBB2KDREPHB4 | |
| SCHEMBL13606789 | 0.93 | EGFR (0.77) | EGFRERBB2EPHA2KDREPHB4 | |
| SCHEMBL4523002 | 0.93 | EGFR (0.77) | EGFRERBB2EPHA2KDREPHB4 | |
| SCHEMBL4524312 | 0.93 | EGFR (0.77) | EGFRERBB2EPHA2KDREPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116041339-A | Afatinib intermediate impurity and preparation method and application thereof | 北京民康百草医药科技有限公司 | 2023-05-02 | — | — | CN | claimed |
| EP-4446324-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| WO-2024175999-A2 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | DUNAD THERAPEUTICS LTD. (GB) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024175998-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | DUNAD THERAPEUTICS, LTD. (GB) | 2024-08-29 | — | — | WO | disclosed |
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| CN-114315595-B | Preparation method of carbon-supported iron-based catalyst and application of intermediate synthesis of anticancer inhibitor of carbon-supported iron-based catalyst | 奥锐特药业股份有限公司 | 2023-12-05 | — | — | CN | disclosed |
| EP-4247794-A2 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 Ontario, Inc. (CA) | 2023-09-27 | — | — | EP | disclosed |
| CN-116041339-A | Afatinib intermediate impurity and preparation method and application thereof | 北京民康百草医药科技有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-116041339-A | Afatinib intermediate impurity and preparation method and application thereof | 北京民康百草医药科技有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-110590485-B | FSO 2 N 3 Use in the production of azido compounds | 中宏鑫投资控股(深圳)有限公司 | 2023-04-14 | — | — | CN | disclosed |
| WO-2022106902-A2 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2022-05-27 | — | — | WO | disclosed |
| CN-112898277-B | Preparation method of afatinib intermediate | 扬子江药业集团有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-114315595-A | Preparation method of carbon-supported iron-based catalyst and synthesis application of anti-cancer inhibitor intermediate thereof | 湖南大学 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | ABCG2, ABCB1, ARSA | EGFR 2252/4885ERBB2 1685/4885EPHA2 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.